By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has filed for an initial public offering to sell shares on the NYSE Euronext in Amsterdam.

The Dutch molecular diagnostics firm plans to sell up to 4,587,156 newly issued ordinary shares at a price of between €16.35 to €19.15 per share. At the mid-point of that range, it would raise around €81.4 million ($119 million), before an over-allotment option of up to 688,073 newly issued ordinary shares.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more. 

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.